Heat Biologics Reports Interim Phase 2 Lung Cancer Data On HS-110 + Nivolumab At ASCO-SITC Symposium: 'suggests the addition of HS-110 to Nivolumab may restore responsiveness to treatment after tumor progression on prior checkpoint inhibitor therapy'
Benzinga Newsdesk